

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	CD97; lysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1)	<i>In vitro</i> and mouse studies suggest inhibiting CD97 could help prevent prostate cancer metastasis. In cultured prostate cancer cells, small hairpin RNA against CD97 decreased migration and invasion compared with nonsilencing shRNA. In mice, subcutaneous injection of CD97-depleted cancer cells resulted in a 55% incidence of metastasis compared with 93% for injection of control cancer cells. Next steps include identifying a therapeutic that antagonizes CD97.	Findings patented; available for licensing	Ward, Y. <i>et al. Cancer Res.</i> ; published online Oct. 6, 2011; doi:10.1158/0008-5472.CAN-11-2381 Contact: Kathleen Kelly, Center for Cancer Research, National Cancer Institute, Bethesda, Md. e-mail: kellyka@mail.nih.gov
<p>SciBX 4(43); doi:10.1038/scibx.2011.1207 Published online Nov. 3, 2011</p>				